Differences in the manner of c-Met inhibition and EGFR mutation status may help explain apparently contradictory biomarker results in non-small cell lung cancer reported for two anti-c-Met mAbs, one from Aveo Pharmaceuticals Inc. and the other from Genentech Inc.

Activation of c-Met is thought to trigger tumor cell survival, growth and metastasis in a variety of tumor types.